Skip to main content
Erschienen in: Annals of Surgical Oncology 1/2018

24.10.2017 | Melanomas

Prediction of Non-sentinel Node Status in Patients with Melanoma and Positive Sentinel Node Biopsy: An Italian Melanoma Intergroup (IMI) Study

verfasst von: Carlo Riccardo Rossi, MD, Simone Mocellin, MD, Luca Giovanni Campana, MD, Lorenzo Borgognoni, MD, Serena Sestini, MD, Giuseppe Giudice, MD, Corrado Caracò, MD, Adriana Cordova, MD, Nicola Solari, MD, Dario Piazzalunga, MD, Paolo Carcoforo, MD, Pietro Quaglino, MD, Virginia Caliendo, MD, Simone Ribero, MD, on behalf of the Italian Melanoma Intergroup (IMI)

Erschienen in: Annals of Surgical Oncology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Background and Purpose

Approximately 20% of melanoma patients harbor metastases in non-sentinel nodes (NSNs) after a positive sentinel node biopsy (SNB), and recent evidence questions the therapeutic benefit of completion lymph node dissection (CLND). We built a nomogram for prediction of NSN status in melanoma patients with positive SNB.

Methods

Data on anthropometric and clinicopathological features of patients with cutaneous melanoma who underwent CLND after a positive SNB were collected from nine Italian centers. Multivariate logistic regression was utilized to identify predictors of NSN status in a training set, while model efficiency was validated in a validation set.

Results

Data were available for 1220 patients treated from 2000 through 2016. In the training set (n = 810), the risk of NSN involvement was higher when (1) the primary melanoma is thicker or (2) sited in the trunk/head and neck; (3) fewer nodes are excised and (4) more nodes are involved; and (5) the lymph node metastasis is larger or (6) is deeply located. The model showed high discrimination (area under the receiver operating characteristic curve 0.74, 95% confidence interval [CI] 0.70–0.79) and calibration (Brier score 0.16, 95% CI 0.15–0.17) performance in the validation set (n = 410). The nomogram including these six clinicopathological variables performed significantly better than five other previously published models in terms of both discrimination and calibration.

Conclusions

Our nomogram could be useful for follow-up personalization in clinical practice, and for patient risk stratification while conducting clinical trials or analyzing their results.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Madu MF, Wouters MW, van Akkooi AC. Sentinel node biopsy in melanoma: Current controversies addressed. Eur J Surg Oncol. 2017;43:517–533.CrossRefPubMed Madu MF, Wouters MW, van Akkooi AC. Sentinel node biopsy in melanoma: Current controversies addressed. Eur J Surg Oncol. 2017;43:517–533.CrossRefPubMed
2.
Zurück zum Zitat Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599-609.CrossRefPubMedPubMedCentral Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599-609.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17:757-67.CrossRefPubMed Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17:757-67.CrossRefPubMed
4.
Zurück zum Zitat Faries MB, Thompson JF, Cochran AJ, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med. 2017;376:2211-22.CrossRefPubMedPubMedCentral Faries MB, Thompson JF, Cochran AJ, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med. 2017;376:2211-22.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Pasquali S, Mocellin S, Mozzillo N, et al. Nonsentinel lymph node status in patients with cutaneous melanoma: results from a multi-institution prognostic study. J Clin Oncol. 2014;32:935-41.CrossRefPubMed Pasquali S, Mocellin S, Mozzillo N, et al. Nonsentinel lymph node status in patients with cutaneous melanoma: results from a multi-institution prognostic study. J Clin Oncol. 2014;32:935-41.CrossRefPubMed
6.
Zurück zum Zitat Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599-609.CrossRefPubMedPubMedCentral Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599-609.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Testori A, De Salvo GL, Montesco MC, et al. Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI). Ann Surg Oncol. 2009;16:2018-27.CrossRefPubMed Testori A, De Salvo GL, Montesco MC, et al. Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI). Ann Surg Oncol. 2009;16:2018-27.CrossRefPubMed
8.
Zurück zum Zitat Sauerbrei W, Royston P, Binder H. Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med. 2007;26:5512-28.CrossRefPubMed Sauerbrei W, Royston P, Binder H. Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med. 2007;26:5512-28.CrossRefPubMed
9.
Zurück zum Zitat Bagherzadeh-Khiabani F, Ramezankhani A, Azizi F, et al. A tutorial on variable selection for clinical prediction models: feature selection methods in data mining could improve the results. J Clin Epidemiol. 2016;71:76-85.CrossRefPubMed Bagherzadeh-Khiabani F, Ramezankhani A, Azizi F, et al. A tutorial on variable selection for clinical prediction models: feature selection methods in data mining could improve the results. J Clin Epidemiol. 2016;71:76-85.CrossRefPubMed
10.
Zurück zum Zitat Schmidt, CH, Griffith JL. Multivariate classification rules: calibration and discrimination. In: Armitage P, Colton T (eds). Encyclopedia of biostatistics, vol. 2. Chichester: Wiley; 2005. pp. 3492-3494. Schmidt, CH, Griffith JL. Multivariate classification rules: calibration and discrimination. In: Armitage P, Colton T (eds). Encyclopedia of biostatistics, vol. 2. Chichester: Wiley; 2005. pp. 3492-3494.
11.
Zurück zum Zitat Cleveland WS. Robust locally weighted fitting and smoothing scatterplots. J Am Stat Assoc. 1979:74, 829-36.CrossRef Cleveland WS. Robust locally weighted fitting and smoothing scatterplots. J Am Stat Assoc. 1979:74, 829-36.CrossRef
12.
Zurück zum Zitat Kibrité A, Milot H, Douville P, et al. Predictive factors for sentinel lymph nodes and non-sentinel lymph nodes metastatic involvement: a database study of 1,041 melanoma patients. Am J Surg. 2016;211:89-94.CrossRefPubMed Kibrité A, Milot H, Douville P, et al. Predictive factors for sentinel lymph nodes and non-sentinel lymph nodes metastatic involvement: a database study of 1,041 melanoma patients. Am J Surg. 2016;211:89-94.CrossRefPubMed
13.
Zurück zum Zitat Sabel MS, Griffith K, Sondak VK, et al. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. J Am Coll Surg. 2005;201:37-47.CrossRefPubMed Sabel MS, Griffith K, Sondak VK, et al. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. J Am Coll Surg. 2005;201:37-47.CrossRefPubMed
14.
Zurück zum Zitat Gershenwald JE, Andtbacka RH, Prieto VG, et al. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol. 2008;26:4296-303.CrossRefPubMedPubMedCentral Gershenwald JE, Andtbacka RH, Prieto VG, et al. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol. 2008;26:4296-303.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Lee JH, Essner R, Torisu-Itakura H, et al. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol. 2004;22:3677-84.CrossRefPubMed Lee JH, Essner R, Torisu-Itakura H, et al. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol. 2004;22:3677-84.CrossRefPubMed
16.
Zurück zum Zitat Murali R, Desilva C, Thompson JF, et al. Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. J Clin Oncol. 2010;28:4441-9.CrossRefPubMed Murali R, Desilva C, Thompson JF, et al. Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. J Clin Oncol. 2010;28:4441-9.CrossRefPubMed
17.
Zurück zum Zitat Mocellin S, Lens MB, Pasquali S, et al. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Rev. 2013;6:8955. Mocellin S, Lens MB, Pasquali S, et al. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Rev. 2013;6:8955.
18.
Zurück zum Zitat Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage iii melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375:1845-1855.CrossRefPubMedPubMedCentral Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage iii melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375:1845-1855.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Iasonos A, Schrag D, Raj GV, et al. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26:1364-70.CrossRefPubMed Iasonos A, Schrag D, Raj GV, et al. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26:1364-70.CrossRefPubMed
20.
Zurück zum Zitat Damude S, Hoekstra HJ, Bastiaannet E, et al. The predictive power of serum S-100B for non-sentinel node positivity in melanoma patients. Eur J Surg Oncol. 2016;42:545-51.CrossRefPubMed Damude S, Hoekstra HJ, Bastiaannet E, et al. The predictive power of serum S-100B for non-sentinel node positivity in melanoma patients. Eur J Surg Oncol. 2016;42:545-51.CrossRefPubMed
21.
Zurück zum Zitat Liang F, Qu H, Lin Q, et al. Molecular biomarkers screened by next-generation RNA sequencing for non-sentinel lymph node status prediction in breast cancer patients with metastatic sentinel lymph nodes. World J Surg Oncol. 2015;13:258.CrossRefPubMedPubMedCentral Liang F, Qu H, Lin Q, et al. Molecular biomarkers screened by next-generation RNA sequencing for non-sentinel lymph node status prediction in breast cancer patients with metastatic sentinel lymph nodes. World J Surg Oncol. 2015;13:258.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Kwon Y, Ro J, Kang HS, et al. Clinicopathological parameters and biological markers predicting non-sentinel node metastasis in sentinel node-positive breast cancer patients. Oncol Rep. 2011;25:1063-71.PubMed Kwon Y, Ro J, Kang HS, et al. Clinicopathological parameters and biological markers predicting non-sentinel node metastasis in sentinel node-positive breast cancer patients. Oncol Rep. 2011;25:1063-71.PubMed
23.
Zurück zum Zitat Pasquali S, van der Ploeg AP, Mocellin S, et al. Lymphatic biomarkers in primary melanomas as predictors of regional lymph node metastasis and patient outcomes. Pigment Cell Melanoma Res. 2013;26:326-37.CrossRefPubMed Pasquali S, van der Ploeg AP, Mocellin S, et al. Lymphatic biomarkers in primary melanomas as predictors of regional lymph node metastasis and patient outcomes. Pigment Cell Melanoma Res. 2013;26:326-37.CrossRefPubMed
Metadaten
Titel
Prediction of Non-sentinel Node Status in Patients with Melanoma and Positive Sentinel Node Biopsy: An Italian Melanoma Intergroup (IMI) Study
verfasst von
Carlo Riccardo Rossi, MD
Simone Mocellin, MD
Luca Giovanni Campana, MD
Lorenzo Borgognoni, MD
Serena Sestini, MD
Giuseppe Giudice, MD
Corrado Caracò, MD
Adriana Cordova, MD
Nicola Solari, MD
Dario Piazzalunga, MD
Paolo Carcoforo, MD
Pietro Quaglino, MD
Virginia Caliendo, MD
Simone Ribero, MD
on behalf of the Italian Melanoma Intergroup (IMI)
Publikationsdatum
24.10.2017
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 1/2018
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-017-6143-5

Weitere Artikel der Ausgabe 1/2018

Annals of Surgical Oncology 1/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.